atezolizumab plus bevacizumab (n=276) vs. sunitinib (n=277)
randomized controlled trial
atezolizumab plus bevacizumab
atezolizumab 1200 mg intravenously then bevacizumab 15 mg/kg intravenous infusions once every 3 weeks.
Sunitinib
sunitinib 50 mg once daily orally for 4 weeks, followed by 2 weeks of rest
No prespecified crossover was planned per protocol. Patients could continue atezolizumab plus bevacizumab or sunitinib
mRCC - L1 - PDL1 negative
Patients were excluded if they had received previous systemic treatment or if they had untreated brain metastases.
open label
152 sites across 21 countries
P3 / two-sided test procedure with two interim analysis. AI 1 (12 months) repartition between coprmary endpoints (0.04 PFS and 0.01 OS) and then hierarchy with OS (PDL1>1%)
Atezolizumab plus bevacizumab did not significantly prolonged progression-free survival versus sunitinib in patients with metastatic renal cell carcinoma but showed a favourable safety profile. exploratory results for this arm